Thus, the complexity of the immune mechanisms at play in HT and this first report on a potential role of PD-1/PD-L1 in the CD4+ T cell dysfunction underlying HT call for further in-depth studies involving a large sample size and functional approaches to elucidate the exact implication of this pathway in HT pathogenesis. The gene discussed is PDCD1; the disease is hematocrit.